Zacks: Brokerages Expect Xencor, Inc. (XNCR) to Announce -$0.34 Earnings Per Share
Analysts expect Xencor, Inc. (NASDAQ:XNCR) to announce earnings of ($0.34) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Xencor’s earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.49). Xencor reported earnings per share of ($0.21) in the same quarter last year, which suggests a negative year over year growth rate of 61.9%. The company is expected to report its next earnings results on Tuesday, February 27th.
On average, analysts expect that Xencor will report full-year earnings of ($1.13) per share for the current year, with EPS estimates ranging from ($1.29) to ($1.04). For the next year, analysts forecast that the firm will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.12) to ($1.15). Zacks’ EPS averages are a mean average based on a survey of analysts that follow Xencor.
Several research firms have weighed in on XNCR. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price target on shares of Xencor in a research report on Tuesday, August 8th. Zacks Investment Research upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. BidaskClub downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Piper Jaffray Companies restated a “buy” rating and set a $35.00 price objective on shares of Xencor in a research report on Sunday, November 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $30.80.
In related news, major shareholder John S. Stafford III bought 150,000 shares of the business’s stock in a transaction that occurred on Friday, October 27th. The stock was bought at an average cost of $19.81 per share, with a total value of $2,971,500.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder John S. Stafford III bought 3,400 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average cost of $19.89 per share, with a total value of $67,626.00. The disclosure for this purchase can be found here. Insiders have bought a total of 263,105 shares of company stock worth $5,206,858 over the last 90 days. Insiders own 4.14% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of XNCR. FMR LLC grew its stake in Xencor by 77.7% during the second quarter. FMR LLC now owns 6,690,258 shares of the biopharmaceutical company’s stock valued at $141,232,000 after acquiring an additional 2,924,510 shares in the last quarter. State Street Corp grew its stake in Xencor by 17.5% during the first quarter. State Street Corp now owns 992,981 shares of the biopharmaceutical company’s stock valued at $23,751,000 after acquiring an additional 148,136 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Xencor by 57.4% during the first quarter. Dimensional Fund Advisors LP now owns 286,894 shares of the biopharmaceutical company’s stock valued at $6,863,000 after acquiring an additional 104,638 shares in the last quarter. Artal Group S.A. purchased a new position in Xencor during the third quarter valued at $2,292,000. Finally, JPMorgan Chase & Co. grew its stake in Xencor by 48.1% during the second quarter. JPMorgan Chase & Co. now owns 289,500 shares of the biopharmaceutical company’s stock valued at $6,112,000 after acquiring an additional 93,975 shares in the last quarter. 77.61% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/11/30/zacks-brokerages-expect-xencor-inc-xncr-to-announce-0-34-earnings-per-share.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.